p21WAF-1/Cip-1 gene therapy as an adjunct to glaucoma filtration surgery

Current Opinion in Molecular Therapeutics

Volumn 6, Issue 6, 2004, Pages 624-628

  Atencio, Isabella A ^a   Chen, Zoe ^a   Nguyen, Quang H ^a   Faha, Barbara ^a   Maneval, Daniel C ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Adenovirus gene therapy; Antiproliferative; Conjunctiva wound healing; Glaucoma filtration surgery; p21WAF 1 Cip 1

Indexed keywords

ADENOVIRUS VECTOR; CYCLIN DEPENDENT KINASE INHIBITOR 1; FLUOROURACIL; LERDELIMUMAB; MITOMYCIN C; PLATELET DERIVED GROWTH FACTOR; PROTEIN P53; RAD50 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA2; CDKN1A PROTEIN, HUMAN; CELL CYCLE PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 1A;

CLINICAL TRIAL; CORNEA DISEASE; CORNEA EROSION; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SAFETY; ENDOPHTHALMITIS; EXPERIMENTAL MODEL; FILTERING OPERATION; GLAUCOMA; HUMAN; INTRAOCULAR PRESSURE ABNORMALITY; MUSCLE HYPOTONIA; NONHUMAN; REVIEW; SCAR FORMATION; TISSUE DEGENERATION; TREATMENT FAILURE; TREATMENT OUTCOME; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; WOUND HEALING IMPAIRMENT; ANIMAL; GENE THERAPY; GENETICS; GLAUCOMA DRAINAGE IMPLANT; METHODOLOGY;

ADENOVIRIDAE;

ANIMALS; CELL CYCLE PROTEINS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; GENE THERAPY; GLAUCOMA DRAINAGE IMPLANTS; HUMANS;

EID: 11344263706     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (47)

1. Quigley HA: Number of people with glaucoma worldwide. Br J Ophthalmol (1996) 80(5):389-393.
2. Quigley HA, Enger C, Katz J, Sommer A, Scott R, Gilbert D: Risk factors for the development of glaucomatous visual field loss in ocular hypertension. Arch Ophthalmol (1994) 112 5):644-649.
3. Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M: Reduction of intraocular pressure and glaucoma progression: Results from the Early Manifest Glaucoma Trial. Arch Ophthalmol (2002) 120(10):1268-1279.
4. Leske MC, Heijl A, Hyman L, Bengtsson B: Early Manifest Glaucoma Trial: Design and baseline data. Ophthalmology (1999) 106(11):2144-2153.
5. Leske MC, Heijl A, Hussein M, Bengtsson B, Hyman L, Komaroff E: Factors for glaucoma progression and the effect of treatment: The Early Manifest Glaucoma Trial. Arch Oplithalmol (2003) 121 1):48-56.
6. Skuta GL, Parrish RK 2nd: Wound healing in glaucoma filtering surgery. Surv Ophthalmol (1987) 32(3 ):149-170.
7. Jampel HD, McGuigan LJ, Dunkelberger GR, L'Hernault NL, Quigley HA: Cellular proliferation after experimental glaucoma filtration surgery. Arch Ophthalmol (1988) 106(1 ):89-94.
8. Denk PO, Hoppe J, Hoppe V, Knorr M: Effect of growth factors on the activation of human Tenon's capsule fibroblasts. Curr Eye Res (2003) 27(1):35-44.
9. Liebmann JM, Ritch R, Marmor M, Nunez J, Wolner B: Initial 5-fluorouracil trabeculectomy in uncomplicated glaucoma. Ophthalmology (1991) 98(7):1036-1041.
10. Kupin TH, Juzych MS, Shin DH, Khatana AK, Olivier MM: Adjunctive mitomycin C in primary trabeculectomy in phakic eyes. Am J Ophthalmol (1995) 119(1):30-39.
11. Lama PJ, Fechtner RD: Antifibrotics and wound healing in glaucoma surgery. Surv Ophthalmol (2003) 48(3):314-346.
12. Scott IU, Greenfield DS, Schiffman J, Nicolela MT, Rueda JC, Tsai JC, Palmberg PF: Outcomes of primary trabeculectomy with the use of adjunctive mitomycin. Arch Ophthalmol (1998) 116 3):286-291.
13. Smith MF, Sherwood MB, Doyle JW, Khaw PT: Results of intraoperative 5-fluorouracil supplementation on trabeculectomy for open-angle glaucoma. Am J Ophthalmol (1992) 114 6):737-741.
14. Membrey WL, Bunce C, Poinoosawmy DP, Fitzke FW, Hitchings RA: Glaucoma surgery with or without adjunctive antiproliferatives in normal tension glaucoma: 2 Visual field progression. Br J Ophthalmol (2001) 86(6):696-701.
15. Membrey WL, Poinoosawmy DP, Bunce C, Hitchings RA: Glaucoma surgery with or without adjunctive antiproliferatives in normal tension glaucoma: 1 Intraocular pressure control and complications. Br J Ophthalmol (2000) 84(6):586-590.
16. Risk factors for suprachoroidal hemorrhage after filtering surgery. The Fluorouracil Filtering Surgery Study Group. Am J Ophthalmol (1992) 113(5):501-507.
17. Costa VP, Wilson RP, Moster MR, Schmidt CM, Gandham S: Hypotony maculopathy following the use of topical mitomycin C in glaucoma filtration surgery. Ophthalmic Surg (1993) 24(6):389-394.
18. Greenfield DS, Suner IJ, Miller MP, Kangas TA, Palmberg PF, Flynn HW Jr: Endophthalmitis after filtering surgery with mitomycin. Arch Ophthalmol (1996) 114(8):943-949.
19. Higginbotham EJ, Stevens RK, Musch DC, Karp KO, Lichter PR, Bergstrom TJ, Skuta GL: Bleb-related endophthalmitis after trabeculectomy with mitomycin C. Ophthalmology (1996) 103 4):650-656.
20. Stamper RL, McMenemy MG, Lieberman MF: Hypotonous maculopathy after trabeculectomy with subconjunctival 5-fluorouracil. Am J Ophthalmol (1992) 114(5):544-553.
21. Wolner B, Liebmann JM, Sassani JW, Ritch R, Speaker M, Marmor M: Late bleb-related endophthalmitis after trabeculectomy with adjunctive 5-fluorouracil. Ophthalmology (1991) 98 7):1053-1060.
22. Bindlish R, Condon GP, Schlosser JD, D'Antonio J, Lauer KB, Lehrer R: Efficacy and safety of mitomycin-C in primary trabeculectomy: Five-year follow-up. Ophthalmology (2002) 109 7):1336-1341.
23. Akarsu C, Onol M, Hasanreisoglu B: Postoperative 5-fluorouracil versus intraoperative mitomycin C in high-risk glaucoma filtering surgery: Extended follow up. Clin Experiment Ophthalmol (2003) 31(3):199-205.
24. Khan AM, Jilani FA, Das S: The role of 5-fluorouracil in complicated glaucomas. Indian J Ophthalmol (1993) 41 2):74-77.
25. Perkins TW, Gangnon R, Ladd W, Kaufman PL, Heatley GA: Trabeculectomy with mitomycin C: Intermediate-term results. J Glaucoma (1998) 7(4):230-236.
26. Cordeiro MF, Gay JA, Khaw PT: Human anti-transforming growth factor-β2 antibody: A new glaucoma anti-scarring agent. Invest Ophthalmol Vis Sci (1999) 40(10):2225-2234.
27. Hill C, Flyvbjerg A, Rasch R, Bak M, Logan A: Transforming growth factor-β2 (TGF-β2) antibody attenuates fibrosis in the experimental diabetic rat kidney. J Endocrinol (2001) 170 3):647-651.
28. Cordeiro MF: Role of transforming growth factor β in conjunctival scarring. Clin Sci (2003) 104(2):181-187.
29. Mead AL, Wong TT, Cordeiro MF, Anderson IK, Khaw PT: Evaluation of anti-TGF-β2 antibody as a new postoperative anti-scarring agent in glaucoma surgery. Invest Ophthalmol Vis Sci (2003) 44(8):3394-3401.
30. Siriwardena D, Khaw PT, King AJ, Donaldson ML, Overton BM, Migdal C, Cordeiro MF: Human antitransforming growth factor β2 monoclonal antibody - a new modulator of wound healing in trabeculectomy: A randomized placebo controlled clinical study. Ophthalmology (2002) 109(3):427-431.
31. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B: WAF1, a potential mediator of p53 tumor suppression. Cell (1993) 75(4):817-825.
32. 1 cyclin-dependent kinases. Cell (1993) 75(4):805-816.
33. Gartel AL, Serfas MS, Tyner AL: p21 - negative regulator of the cell cycle. Proc Soc Exp Biol Med (1996) 213 2):138-149.
34. Eastham JA, Hall SJ, Sehgal I, Wang J, Timme TL, Yang G, Connell-Crowley L, Elledge SJ, Zhang WW, Harper JW et al: In vivo gene therapy with p53 or p21 adenovirus for prostate cancer. Cancer Res (1995) 55(22):5151-5155.
35. Meng RD, Shih H, Prabhu NS, George DL, el-Deiry WS: Bypass of abnormal MDM2 inhibition of p63 -dependent growth suppression. Clin Cancer Res (1998) 4(1):251-259.
36. Yang ZY, Perkins ND, Ohno T, Nabel EG, Nabel GJ: The p21 cyclin-dependent kinase inhibitor suppresses tumorigenicity in vivo. Nat Med (1995) 1(10):1052-1056.
37. WAF1 adenoviral gene transfer in lung cancer. Cancer Gene Ther (1998) 5 3):183-191.
38. WAF1/Cip for potential use in ocular gene therapy. Preclinica (2003) 1(4):187-197.
39. WAF-1/Cip-1 to prevent wound healing in a rabbit model of glaucoma filtration surgery. Arch Ophthalmol (2002) 120(7):941-949.
40. Wen SF, Chen Z, Nery J, Faha B: Characterization of adenovirus p21 gene transfer, biodistribution, and immune response after local ocular delivery in New Zealand white rabbits. Exp Eye Res (2003) 77(3):355-365.
41. WAF-1/Cip-1 to modulate wound healing after glaucoma trabeculectomy surgery in a primate model of ocular hypertension. Gene Ther (2004) 11(12):949-955.
42. Yoon KC, Yang KJ, Seo JS, Lee SE, Heo T, Chun BJ, Jung S, Kim KK, Ahn KY: Effect of human RAD50 gene therapy on glaucoma filtering surgery in rabbit eye. Curr Eye Res (2004) 28(3 ):181-187.
43. Campochiaro PA: Gene therapy for retinal and choroidal diseases. Expert Opin Biol Ther (2002) 2(5):537-544.
44. Chevez-Barrios P, Chintagumpala M, Boniuk M, Hurwitz MY, Hurwitz RL: Gene therapy for retinoblastoma: Report of a pilot clinical study. Invest Ophthalmol Vis Sci (2002) 43:Abs 2895.
45. Chevez-Barrios P, Chintagumpala M, Mieler W, Paysse E, Boniuk M, Hurwitz MY, Hurwitz RL: Response of retinoblastoma with vitreous seeds to suicide gene therapy using adenoviral-mediated delivery of thymidine kinase followed by ganciclovir. Invest Ophthalmol Vis Sci (2004) 45:Abs 3360.
46. Rasmussen H, Chu KW, Campochiaro P, Gehlbach PL, Haller JA, Handa JT, Nguyen QD, Sung JU: Clinical protocol. An open-label, phase I, single administration, dose-escalation study of AdGVPEDF.11D (AdPEDF) in neovascular age-related macular degeneration (AMD). Hum Gene Ther (2001) 12(16):2029-2032.
47. Bennett J: Gene therapy for Leber congenital amaurosis. Novartis Foundation Symposium (2004) 255:195-202.